Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemo + Lorlatinib in ALK+ NSCLC
NCT06378892Phase 2Recruiting
- Sponsor
- Centro di Riferimento Oncologico di Aviano
- Start
- Mar 2024
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Centro di Riferimento Oncologico di Aviano. Started Mar 2024; status: recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06378892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378892.